- Raw materials
- Antimetabolites
- Meglutol
Meglutol API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Meglutol | CAS No: 503-49-1 | GMP-certified suppliers
A medication that lowers cholesterol and triglycerides by modulating lipid metabolism, intended for investigational use in managing hyperlipidemia and related cardiovascular risk factors.
Therapeutic categories
Product Snapshot
- Meglutol is available as oral capsules and tablets, classified as small molecule formulations
- It is primarily developed for metabolic disorders and related conditions
- Currently, Meglutol is in the experimental stage and has not received FDA or EMA approval
Clinical Overview
Pharmacologically, meglutol exerts its lipid-lowering effects primarily through interference with the enzymatic cascade responsible for converting acetate to hydroxymethylglutaryl coenzyme A (HMG-CoA). It further inhibits the activity of HMG-CoA reductase, the rate-limiting enzyme in the biosynthesis of cholesterol. By modulating this pathway, meglutol effectively reduces levels of cholesterol, triglycerides, serum beta-lipoproteins, and phospholipids. Despite its clearly defined biochemical activity, specific clinical indications for meglutol have not been formally established, and it remains an investigational compound.
The pharmacokinetic profile (absorption, distribution, metabolism, and excretion) of meglutol is not comprehensively documented in the current literature. Similarly, detailed pharmacodynamic parameters and comprehensive mechanism-of-action studies beyond its enzyme inhibition effect are limited. Safety and toxicity data are sparse; hence, no conclusive risk profile or adverse effect spectrum has been delineated to date.
Meglutol has not attained regulatory approval and lacks marketed pharmaceutical formulations. Usage contexts remain confined to experimental and research settings, with no notable commercial brand associations.
For API sourcing and quality considerations, it is essential that procurement prioritize suppliers with validated synthetic routes ensuring high purity and batch-to-batch consistency. Analytical characterization must confirm structural integrity and absence of impurities related to incomplete synthesis or degradation. Given its experimental status, documentation supporting API compliance with applicable pharmacopeial or regulatory standards should be rigorously reviewed.
Identification & chemistry
| Generic name | Meglutol |
|---|---|
| Molecule type | Small molecule |
| CAS | 503-49-1 |
| UNII | CLA99KCD53 |
| DrugBank ID | DB04377 |
Pharmacology
Targets
| Target | Organism | Actions |
|---|---|---|
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Humans |
Formulation & handling
- Meglutol is a small molecule hydroxy fatty acid suitable for oral dosage forms such as capsules and tablets.
- The compound exhibits high water solubility and low logP, indicating favorable oral bioavailability and formulation flexibility.
- Stability considerations should focus on maintaining solid form integrity, with no specific sensitivity to food intake reported.
Regulatory status
Meglutol is a type of Antimetabolites
Antimetabolites are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) utilized in the treatment of various diseases, particularly cancer. These compounds are structurally similar to naturally occurring metabolites essential for cellular processes such as DNA and RNA synthesis. By mimicking these metabolites, antimetabolites interfere with the normal functioning of cellular pathways, leading to inhibition of cancer cell growth and proliferation.
One of the widely used antimetabolites is methotrexate, a folic acid antagonist that inhibits the enzyme dihydrofolate reductase, disrupting the production of DNA and RNA. This disruption impedes the growth of rapidly dividing cancer cells. Another common antimetabolite is 5-fluorouracil (5-FU), which inhibits the enzyme thymidylate synthase, thereby interfering with DNA synthesis and inhibiting cancer cell proliferation.
Antimetabolites can be classified into several subcategories based on their mechanism of action and chemical structure. These include purine and pyrimidine analogs, folic acid antagonists, and pyrimidine synthesis inhibitors. Examples of antimetabolites in these subcategories include azathioprine, cytarabine, and gemcitabine.
Despite their effectiveness, antimetabolites can exhibit certain side effects due to their interference with normal cellular processes. These side effects may include gastrointestinal disturbances, myelosuppression (reduced production of blood cells), and hepatotoxicity.
In conclusion, antimetabolites are a vital category of pharmaceutical APIs used in the treatment of various diseases, especially cancer. By mimicking natural metabolites and disrupting crucial cellular processes, these compounds effectively inhibit cancer cell growth and proliferation. However, their usage should be carefully monitored due to potential side effects.
